ArticleBiotechnology letters2025
Designing a multi-epitope vaccine against the midgut-specific fibrinogen-related protein 1(FREP1) of Anopheles stephensi to enhance protection against the malaria parasite: a step beyond traditional vaccine development approaches.
Article in Biotechnology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malaria has been a prominent health burden for decades globally. The complex life cycle of Plasmodium made numerous challenges in finding an effective candidate for developing a potent transmission-blocking vaccine (TBV) against malaria. A wide variety of genes of Anopheles mosquitoes' midgut and salivary gland play a pivotal role in the Plasmodium invasion and transmission inside the mosquito body. Targeting mosquitoes' genes offered new insights into developing a more efficient TBV with higher potential to impede the parasite transmission within the Anopheles. Fibrinogen-related protein 1(FREP1) is a mosquito midgut protein that plays a crucial role in parasite transmission. In this study, we opted for an immunoinformatic approach to target An. stephensi FREP1 protein for breaking the parasite cycle so that the life cycle of the parasite could be broken within the mosquito. The FREP1 vaccine was assessed for allergenicity, antigenicity, toxicity, immunogenicity, population coverage, conservancy, solubility, secondary and tertiary structure, which suggested the impeccable quality of the vaccine construct. The interaction between the vaccine and TLR4 receptor via molecular docking revealed an efficient, strong, and stable complex formation. The molecular dynamic simulation and in-silico immunization profiling indicated the remarkable free binding energy and higher potency of the vaccine to generate a significant immune response, respectively. Furthermore, codon optimization and in-silico cloning of the vaccine in Escherichia coli exhibited efficient protein expression. In summary, the FREP1 protein-based multiepitope vaccine can be considered an innovative formulation for targeting the parasite within the vector to impede malaria transmission and vector control as well.
Indexed as
Identifiers
40900278What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.